From
foolmart.com
Email Address
fool@info.fool.com
Sent On
Sat, Apr 27, 2024 01:04 PM
Email Preheader Text
Now's your chance to tap into the next wave—from $6B to $100 billion in just 6 years. ͏
HTML
Now's your chance to tap into the next waveâfrom $6B to $100 billion in just 6 years.
Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  Í â  â  [The Motley Fool] From $6 Billion â $100 Billion by 2030 Donât miss the projected meteoric growth for this weight loss sector. Save 75%* today and get access to our full report before the rest of the public catches on. [75% Discount] [Unlock Your Access For 75% Off*](~/AAQRxQA~/RgRoD3z5P4QcAWh0dHBzOi8vYXBpLmZvb2wuY29tL2luZm90cm9uL3NwbGl0dGVyL3JvdXRlL3NmLXNhLTc1LW96LXNvP2xpZD1jY3VidW44djcyaHEmYXBpa2V5PTVjOGU1MmRkLTFiZWEtNDU1ZS04N2Y1LWQ1NTA2ZTU5MGYyMSZzb3VyY2U9aXNhc28zZW1sMDAwODQzMSZ1PTIwNDY2NTU4MTMmbWFpbGluZ19pZD0zNjBmZDAyZi1lYWM1LTQ3ZjItYjk3OC05YWU4ZTBiZjI1OGImbWFpbGluZ19uYW1lPVZhcmlhbnQgMSZ1dG1fY2FtcGFpZ249b3otbWV0ZW9yaWMmdXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPXNvVwNzcGNCCmYn-fcsZuLlbnhSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAAB-Q~~) â From $6 Billion â $100 Billion by 2030 Donât miss the projected meteoric growth for this weight loss sector. Save 75%* today and get access to our full report before the rest of the public catches on. [Unlock Your Access For 75% Off*](~/AAQRxQA~/RgRoD3z5P4QcAWh0dHBzOi8vYXBpLmZvb2wuY29tL2luZm90cm9uL3NwbGl0dGVyL3JvdXRlL3NmLXNhLTc1LW96LXNvP2xpZD1oeTRrYXk5bGpnMW4mYXBpa2V5PTVjOGU1MmRkLTFiZWEtNDU1ZS04N2Y1LWQ1NTA2ZTU5MGYyMSZzb3VyY2U9aXNhc28zZW1sMDAwODQzMSZ1PTIwNDY2NTU4MTMmbWFpbGluZ19pZD0zNjBmZDAyZi1lYWM1LTQ3ZjItYjk3OC05YWU4ZTBiZjI1OGImbWFpbGluZ19uYW1lPVZhcmlhbnQgMSZ1dG1fY2FtcGFpZ249b3otbWV0ZW9yaWMmdXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPXNvVwNzcGNCCmYn-fcsZuLlbnhSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAAB-Q~~) [75% Discount] The health sector is on the brink of a revolution, with GLP-1 agonists like Ozempic and Wegovy leading the charge. Projected to surge more than 16X by 2030, this market offers an unparalleled opportunity for savvy investors. As celebrities like Elon Musk and Oprah Winfrey, alongside everyday Americans embrace these treatments, the economic reverberations are enormous, shaking the very foundations of numerous established sectors. Walmart, Hershey's, PepsiCo, and even the longstanding Jenny Craig â they've all felt the pinch as this new pharmaceutical marvel shifts consumer habits and health trends. This is being touted by the media as âThe Ozempic Effect.â Now, if you're like me, youâre more interested in fattening your portfolio than trimming a few pounds. And the opportunity to do just that is knocking right now. We first recommended the maker of Ozempic, Novo Nordisk, back in 2015, when Ozempic was undergoing clinical trials. That recommendation has already made members 613%. Now, weâve identified more companies poised to prosper as GLP-1 drugs sweep into Americaâs mainstream. Like another pharmaceutical company with a GLP-1 drug in clinical trials â a drug that is already showing longerâlasting effects than competitors on the market⦠with only a single dose per month. This could be an opportunity to get in on the next Ozempic⦠perhaps a drug that could be even bigger than Ozempic⦠before it hits the market. We've also pinpointed a key player in the healthcare sector that's essential to the distribution of America's most buzzed-about GLP-1 therapies. This company's vast network ensures these transformative drugs reach every corner of the country. As GLP-1 treatments become more mainstream, this behind-the-scenes giant is quietly positioning itself for substantial growth. We have the names of these two companies, along with two others we think will see a BOOM from The Ozempic Effect. And weâve written them up in a detailed report. The only catch? This information is so valuable that weâve only made it available to an exclusive group â our Stock Advisor members. However, today, you can get 75% off* Stock Advisor (which is currently beating the market by over 4.5X), and receive instant access to the report. And if youâre not completely impressed with the stocks inside, you can request your membership fee back, thanks to our 30-day membership fee-back guarantee. But donât wait too long. These stocks are likely to catch on with mainstream investors sooner than later and you donât want to be the last to know. [Read The Report Now](~/AAQRxQA~/RgRoD3z5P4QcAWh0dHBzOi8vYXBpLmZvb2wuY29tL2luZm90cm9uL3NwbGl0dGVyL3JvdXRlL3NmLXNhLTc1LW96LXNvP2xpZD0zZXJiajl0bGFsdXomYXBpa2V5PTVjOGU1MmRkLTFiZWEtNDU1ZS04N2Y1LWQ1NTA2ZTU5MGYyMSZzb3VyY2U9aXNhc28zZW1sMDAwODQzMSZ1PTIwNDY2NTU4MTMmbWFpbGluZ19pZD0zNjBmZDAyZi1lYWM1LTQ3ZjItYjk3OC05YWU4ZTBiZjI1OGImbWFpbGluZ19uYW1lPVZhcmlhbnQgMSZ1dG1fY2FtcGFpZ249b3otbWV0ZW9yaWMmdXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPXNvVwNzcGNCCmYn-fcsZuLlbnhSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAAB-Q~~) â â *Returns as of 4/23/2024 How did you like this email? [Positive](~/AAQRxQA~/RgRoD3z5P0SaaHR0cHM6Ly93d3cuZm9vbC5jb20vbW1zL21hcmsvc2EtcG9zdC1zdXJ2ZXk_bGlkPW1veXpxamowdW13dCZvcD0xMTE4NSZ1PTIwNDY2NTU4MTMmbWFpbGluZ19pZD0zNjBmZDAyZi1lYWM1LTQ3ZjItYjk3OC05YWU4ZTBiZjI1OGImbWFpbGluZ19uYW1lPVZhcmlhbnQgMVcDc3BjQgpmJ_n3LGbi5W54Uht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAAAfk~) [Negative](~/AAQRxQA~/RgRoD3z5P0SsaHR0cHM6Ly93d3cuZm9vbC5jb20vdmlwL2ludmVzdG9yLWFsZXJ0L3NvLWVtYWlsLXN1cnZleS1mcm93bi8_bGlkPXd6bXZwNTI5ODEzYyZvcD0xMTE4MyZ1PTIwNDY2NTU4MTMmbWFpbGluZ19pZD0zNjBmZDAyZi1lYWM1LTQ3ZjItYjk3OC05YWU4ZTBiZjI1OGImbWFpbGluZ19uYW1lPVZhcmlhbnQgMVcDc3BjQgpmJ_n3LGbi5W54Uht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAAAfk~) â [The Motley Fool Logo] [YouTube](~/AAQRxQA~/RgRoD3z5P0RJaHR0cHM6Ly93d3cueW91dHViZS5jb20vY2hhbm5lbC9VQ3BSUXV5bkJYOVF5OXRQcmNzd3BQYWc_bGlkPTh0ZGt0Z3o0b3Zma1cDc3BjQgpmJ_n3LGbi5W54Uht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAAAfk~) [Twitter](~/AAQRxQA~/RgRoD3z5P0QyaHR0cHM6Ly90d2l0dGVyLmNvbS90aGVtb3RsZXlmb29sP2xpZD05Zm1oMjUyb3o3bDVXA3NwY0IKZif59yxm4uVueFIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQAAAH5) [Instagram](~/AAQRxQA~/RgRoD3z5P0RBaHR0cHM6Ly93d3cuaW5zdGFncmFtLmNvbS90aGVtb3RsZXlmb29sb2ZmaWNpYWwvP2xpZD1ibjZ0eTk2NXhhcjFXA3NwY0IKZif59yxm4uVueFIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQAAAH5) [TikTok](~/AAQRxQA~/RgRoD3z5P0Q-aHR0cHM6Ly93d3cudGlrdG9rLmNvbS9AdGhlbW90bGV5Zm9vbG9mZmljaWFsP2xpZD00c3UxY2QwYnV0bXNXA3NwY0IKZif59yxm4uVueFIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQAAAH5) [LinkedIn](~/AAQRxQA~/RgRoD3z5P0RCaHR0cHM6Ly93d3cubGlua2VkaW4uY29tL2NvbXBhbnkvdGhlLW1vdGxleS1mb29sLz9saWQ9dmlrOXNsbGo4bzF0VwNzcGNCCmYn-fcsZuLlbnhSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAAB-Q~~) [Facebook Icon](~/AAQRxQA~/RgRoD3z5P0Q4aHR0cHM6Ly93d3cuZmFjZWJvb2suY29tL3RoZW1vdGxleWZvb2wvP2xpZD1qbXpza2dyMGZvN2tXA3NwY0IKZif59yxm4uVueFIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQAAAH5) [Pinterest](~/AAQRxQA~/RgRoD3z5P0Q5aHR0cHM6Ly93d3cucGludGVyZXN0LmNvbS90aGVtb3RsZXlmb29sLz9saWQ9cGxsbjkxdXN1ajZ0VwNzcGNCCmYn-fcsZuLlbnhSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAAB-Q~~) 1 Based on $199/year list price. Introductory promotion for new members only. Stock Advisor will renew at the then current list price. Promotional pricing in this email expires at 3:00 AM ET on June 28, 2024. We work fervently, feverishly, and Foolishly to make sure all the facts and figures we publish in our emails are 100% accurate and up to date. This is a promotional message from The Motley Fool | 2000 Duke St. | Alexandria, VA 22314
[Legal Information](~/AAQRxQA~/RgRoD3z5P0SNaHR0cHM6Ly93d3cuZm9vbC5jb20vbGVnYWwvc3R1ZmYtd2Utb3duLz9saWQ9ZG9rdWxyMDB0eXltJnU9MjA0NjY1NTgxMyZtYWlsaW5nX2lkPTM2MGZkMDJmLWVhYzUtNDdmMi1iOTc4LTlhZThlMGJmMjU4YiZtYWlsaW5nX25hbWU9VmFyaWFudCAxVwNzcGNCCmYn-fcsZuLlbnhSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAAB-Q~~). Copyright ©1995-2024 The Motley Fool. All rights reserved. To prevent this from getting swept up by overzealous email filters, add Fool@info.fool.com to your address book. If you no longer wish to receive this email, please [unsubscribe now](~/AAQRxQA~/RgRoD3z5P0SsaHR0cHM6Ly93d3cuZm9vbC5jb20vdW5zdWJzY3JpYmUvYWxsP2xpZD1zYXd1c2s3bjZqNnEmYWNjb3VudF9pZD00YmZlNGVhMy1iNTU0LTQwNjYtOGEyOC04YzVlODZmY2IwMjMmbWFpbGluZ19pZD0zNjBmZDAyZi1lYWM1LTQ3ZjItYjk3OC05YWU4ZTBiZjI1OGImbWFpbGluZ19uYW1lPVZhcmlhbnQgMVcDc3BjQgpmJ_n3LGbi5W54Uht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAAAfk~). Please do not respond to this email as this mailbox is unmonitored. Go to [our help center](~/AAQRxQA~/RgRoD3z5P0QyaHR0cHM6Ly9zdXBwb3J0LmZvb2wuY29tL2hjL2VuLXVzP2xpZD00YWJlZnZwZ2RpbG1XA3NwY0IKZif59yxm4uVueFIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQAAAH5) for answers to frequently asked questions and for options on how to contact us
EDM Keywords (82)
written
want
wait
valuable
unlock
trimming
treatments
touted
think
tap
surge
stocks
see
revolution
rest
respond
request
report
renew
recommendation
receive
publish
prosper
prevent
pounds
portfolio
pinch
pepsico
ozempic
options
opportunity
names
missed
miss
media
market
maker
mainstream
mailbox
made
long
likely
like
later
last
interested
information
identified
hits
get
foundations
foolishly
figures
felt
fattening
facts
even
et
essential
emails
email
drug
distribution
date
country
could
competitors
company
chance
catch
buzzed
brink
boom
behind
available
answers
america
access
75
6b
2030
2015
16x